Conjugated To A Detectable Label Or Radioisotope Or Radionuclide Or Heavy Metal-containing Compound Patents (Class 530/391.3)
-
Publication number: 20140329228Abstract: An object of the present invention is to provide an immunoassay that enables the rapid and convenient quantitative measurement with high detection sensitivity of a target substance in a liquid phase without the need of immobilization and washing steps and enables the visualization of an antigen.Type: ApplicationFiled: November 1, 2012Publication date: November 6, 2014Applicant: Ushio Denki Kabushiki KaishaInventors: Hiroshi Ueda, Ryoji Abe, Hiroaki Takagi
-
Patent number: 8877199Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.Type: GrantFiled: May 12, 2010Date of Patent: November 4, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
-
Publication number: 20140322224Abstract: The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Applicant: ALPER BIOTECH LLCInventor: Ozge Alper
-
Publication number: 20140322246Abstract: In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fc? receptor.Type: ApplicationFiled: October 4, 2011Publication date: October 30, 2014Applicant: KING'S COLLEGE LONDONInventors: Sophia Karagiannis, Andrew Beavil, Frank Nestle
-
Publication number: 20140322818Abstract: A new signal amplification method exploiting the dense atom packing in metallic nanocrystals has been developed for detecting target substances. By dissolving nanocrystals to individual ions that are stoichiometrically converted to chromophores and quantified photometrically, extremely high signal amplification can be achieved. Signal amplification is fully determined by the total number of atoms in the nanocrystals bound to a single target molecule. The disclosed nanocrystal amplification method can be implemented with a rich selection of metal/metal oxide nanocrystals and metal-reactive chromogenic substrates.Type: ApplicationFiled: April 24, 2013Publication date: October 30, 2014Inventors: Gang Bao, Sheng Tong
-
Publication number: 20140322129Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Publication number: 20140322233Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: June 2, 2014Publication date: October 30, 2014Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Publication number: 20140322163Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.Type: ApplicationFiled: December 10, 2012Publication date: October 30, 2014Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
-
Publication number: 20140322130Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: March 26, 2014Publication date: October 30, 2014Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Andrew M. Scott, Terrance Grant Johns, George Mark, Anne Murray, Christoph Renner, Gerd Ritter
-
Publication number: 20140315743Abstract: The invention relates to methods, compositions and kits for the diagnosis, detection, and treatment of ovarian cancer.Type: ApplicationFiled: October 3, 2012Publication date: October 23, 2014Inventors: Karen Chapman, Joseph Wagner, Michael West, Jennifer Lorrie Kidd
-
Publication number: 20140314768Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 6, 2013Publication date: October 23, 2014Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Bruno DOMON, Candy LEE, Tao HE, Mehdi MESRI, Elizabeth JOSELOFF, Katherine MCKINNON, Paul MOORE, Charles BIRSE
-
Publication number: 20140314770Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: February 5, 2014Publication date: October 23, 2014Applicant: Celera CorporationInventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE
-
Publication number: 20140316186Abstract: The present invention is directed towards isolated antibodies that bind to GRP78 and TIP-1.Type: ApplicationFiled: January 28, 2014Publication date: October 23, 2014Inventors: Dennis E. Hallahan, Heping Yan
-
Publication number: 20140314742Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: October 15, 2013Publication date: October 23, 2014Applicant: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez
-
Publication number: 20140314677Abstract: The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. The dyes are particularly useful for in vitro, in vivo and ex vivo imaging applications.Type: ApplicationFiled: March 17, 2014Publication date: October 23, 2014Applicant: VisEn Medical, Inc.Inventors: Kevin Groves, Ryan Buff
-
Patent number: 8865875Abstract: The present invention provides antibodies (e.g., IgG antibodies) having C-terminal cysteine-containing extensions that facilitate antibody conjugation to a partner molecule (e.g. a drug, toxin, marker molecule, protein, radioisotope, or other therapeutic agent). Methods of making, screening and selecting the antibodies of the invention are provided.Type: GrantFiled: August 19, 2008Date of Patent: October 21, 2014Assignee: Medarex, L.L.C.Inventors: Jie Liu, David King
-
Patent number: 8865176Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: GrantFiled: July 16, 2012Date of Patent: October 21, 2014Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20140308201Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.Type: ApplicationFiled: March 11, 2014Publication date: October 16, 2014Applicant: NOVARTIS AGInventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
-
Publication number: 20140308203Abstract: Provided herein are methods for delivering a molecule in situ to a cell and for treating a cancer via the in situ delivery. The methods comprise contacting or administering to the cell, as two separate components, a morpholino oligonucleotide comprising a targeting moiety followed by a single wall nanotube construct comprising second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct. Upon self-assembly of a single wall nanotube complex via hybridization of the first morpholino and second complementary morpholino oligonucleotides at the cell, the payload molecule is delivered. Also provided is the two component self-assembly single wall nanotube system and the single wall nanotube construct comprising the second component.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
-
Publication number: 20140308286Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 19, 2014Publication date: October 16, 2014Applicant: AbbVie Inc.Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
-
Publication number: 20140308278Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: May 28, 2014Publication date: October 16, 2014Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20140301945Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: December 19, 2011Publication date: October 9, 2014Applicants: UNIVERSITY OF ZURICH, NEURIMMUNE HOLDING AGInventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan McAfoose, Marcel Maier
-
Publication number: 20140302050Abstract: Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies.Type: ApplicationFiled: October 24, 2012Publication date: October 9, 2014Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventors: Paraic Anthony Kenny, Kelly Susan Levano Najarro, Eric Hoonee Jung
-
Publication number: 20140302020Abstract: Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: June 23, 2014Publication date: October 9, 2014Inventors: Gilles Bernard TREMBLAY, Mario FILION, Traian SULEA
-
Publication number: 20140303033Abstract: The present invention provides methods and devices for detecting the presence of biomolecules in a biological sample, such as PVL, PBP2a and SPA.Type: ApplicationFiled: November 9, 2012Publication date: October 9, 2014Inventors: Ralf Ehricht, Stefan Monecke, John J. Rejman, Joseph Buechler
-
Publication number: 20140302524Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.Type: ApplicationFiled: February 4, 2014Publication date: October 9, 2014Applicant: GILEAD BIOLOGICS, INC.Inventors: Scott Alan MCCAULEY, Hector RODRIGUEZ, Carlos Aurelio GARCIA, Victoria SMITH
-
Publication number: 20140302043Abstract: The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection.Type: ApplicationFiled: February 3, 2014Publication date: October 9, 2014Applicants: DUKE UNIVERSITY, CHILDREN'S HOSPITAL BOSTONInventors: James Whittle, Stephen C. Harrison, Barton F. Haynes, Hua-Xin Liao, M. Anthomy Moody, Thomas B. Kepler, Aaron G. Schmidt
-
Publication number: 20140302055Abstract: Antibodies directed to the antigen ANGPTL4 and uses of such antibodies. In accordance with the teachings herein, there are provided fully human monoclonal antibodies directed to the antigen ANGPTL4. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: October 15, 2012Publication date: October 9, 2014Inventors: Haihong Zhong, Qing Zhou
-
Patent number: 8853365Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: December 20, 2011Date of Patent: October 7, 2014Assignee: ABBVIE Inc.Inventors: Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
-
Publication number: 20140294841Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.Type: ApplicationFiled: April 2, 2012Publication date: October 2, 2014Applicants: EUREKA THERAPEUTICS, INC., MEMORIAL SLOAN-KETTERING CANCER CENTERInventors: David A. Scheinberg, Tao Dao, Cheng Liu, Su Yan
-
Publication number: 20140294724Abstract: This invention relates to antibody drug conjugates and methods of use thereof. More particularly, antibody drug conjugates comprising a cytoprotective agent are provided, wherein the conjugates are useful for the treatment of proteinopathies such as Alzheimer's disease.Type: ApplicationFiled: October 24, 2012Publication date: October 2, 2014Applicant: INTELLECT NEUROSCIENCES, INC.Inventor: Daniel G. Chain
-
Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
Publication number: 20140294826Abstract: Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a ricin toxin, a Shiga toxin, or an anthrax toxin.Type: ApplicationFiled: April 8, 2014Publication date: October 2, 2014Applicant: Tufts UniversityInventor: Charles B. Shoemaker -
Publication number: 20140294852Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.Type: ApplicationFiled: April 3, 2014Publication date: October 2, 2014Applicants: Ono Pharmaceutical Co., LTD.Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
-
Patent number: 8846875Abstract: Methods, systems and/or kits for the preparation, purification and isolation of oligonucleotide conjugates, comprising conjugation of modified antibodies or proteins with at least one modified oligonucleotide at greater than 80% efficiency to form oligonucleotide conjugates and isolating the oligonucleotide conjugates from the conjugation solution by binding the conjugates to an immobilized binder, wherein the binder may be a metal ion or an antibody.Type: GrantFiled: February 11, 2011Date of Patent: September 30, 2014Assignee: Solulink, Inc.Inventors: David A. Schwartz, Leopoldo G. Mendoza
-
Publication number: 20140286861Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: ApplicationFiled: April 23, 2014Publication date: September 25, 2014Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140286862Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.Type: ApplicationFiled: October 26, 2012Publication date: September 25, 2014Inventors: Sven-Erik Strand, Amanda Thuy Tran, Sven-Niklas Anders Axelsson
-
Publication number: 20140287527Abstract: A method and apparatus for assaying to detect the presence or quantity of an analyte in a test sample, comprising: forming an unbounded aqueous mixture of a first test sample with a defined amount of a nanosphere probe which is conjugate of an analyte capturing member and a long emission fluorescent label, contacting a contacting zone of a test strip with the aqueous mixture, the test area having bound thereat a test binding moiety that for a competition assay binds any sample in competition with the analyte capturing member; or for a sandwich assay binds any sample analyte non-competitively with the analyte capturing member, the control area having bound a control binding moiety to nanosphere probe, selectively measuring long emission fluorescence at the test and control areas, and for a given test strip, determining a test zone value normalized with the total of test and control area signals.Type: ApplicationFiled: March 19, 2013Publication date: September 25, 2014Applicant: LAND AND LONG INTERNATIONAL TRADING CO. LIMITEDInventor: Liwen Xiao
-
Publication number: 20140286859Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.Type: ApplicationFiled: September 10, 2012Publication date: September 25, 2014Applicants: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Publication number: 20140271457Abstract: Engineered multivalent and multispecific binding proteins that bind TNF? and IL-13, TNF? and PGE2, or TNF? and NGF are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: ABBVIE INC.Inventors: Tariq Ghayur, Carrie Goodreau
-
Publication number: 20140273026Abstract: The present invention provides an isolated and purified heat shock protein 60 (Hsp60) peptide having the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a vaccine against Ehrlichia comprising a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to an antibody directed against a peptide homologous to the amino acid sequence of SEQ ID NO:2. The instant invention is also directed to a method of determining whether a subject is infected with Ehrlichia, comprising the steps of: contacting a sample from a subject with the antibody described herein; and detecting a resulting antibody reaction, wherein a positive reaction indicates the subject is infected with Ehrlichia.Type: ApplicationFiled: February 6, 2014Publication date: September 18, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: David H. Walker, Sunil Thomas
-
Publication number: 20140272964Abstract: This invention provides methods of making and using a fluorescent probe from the Sandercyanin protein as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. In one embodiment, the invention provides a method of creating a fluorescent probe, comprising the steps of attaching a Sandercyanin moiety to a probe, wherein the probe is specific to a desired target.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: WiSys Technology Foundation, Inc.Inventors: Wayne Schaefer, Ramaswamy Subramanian, Daniel Ferraro, Chi Li Yu, David Gibson, Swagatha Ghosh, P. Sai Sudha
-
Publication number: 20140271646Abstract: Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.Type: ApplicationFiled: October 16, 2012Publication date: September 18, 2014Inventors: Dimiter S. Dimitrov, Weizao Chen, Yang Feng
-
Publication number: 20140271478Abstract: Provided herein are antibodies with high affinity for the ?8 subunit of ??8.Type: ApplicationFiled: August 17, 2012Publication date: September 18, 2014Applicant: The Regents of the University of CaliforniaInventors: Stephen Nishimura, Jianlong Lou, Jody Lynn Baron, James Marks
-
Publication number: 20140271676Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: Genzyme CorporationInventors: Clark PAN, Huawei QIU
-
Publication number: 20140271477Abstract: The present invention relates to isolated monoclonal anti-EGFR antibodies, and to the use of such antibodies and antibody fragments to detect EGFR, particularly those expressed by cancer cells. The antibodies are useful in diagnostic as well as therapeutic indications. Methods, devices and kits for the immunodetection and immunotherapy of cells expressing EGFR is also encompassed.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: Alper Biotech LLCInventor: Özge ALPER
-
Publication number: 20140271462Abstract: Antigen binding constructs that bind to CD8, for example antibodies, including antibody fragments (such as scFv, minibodies, and cys-diabodies) that bind to CD8, are described herein. Methods of use are described herein.Type: ApplicationFiled: March 10, 2014Publication date: September 18, 2014Applicant: IMAGINAB, INC.Inventors: David T. Ho, Tove Olafsen, Giti Agahi, Christian P. Behrenbruch
-
Publication number: 20140272931Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: Abbott LaboratoriesInventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
-
Publication number: 20140271458Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: AbbVie Inc.Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
-
Publication number: 20140271685Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: BIN LIU
-
Patent number: 8834883Abstract: Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.Type: GrantFiled: June 14, 2011Date of Patent: September 16, 2014Assignee: Vaccinex, Inc.Inventors: Leslie A. Croy, Mark J. Paris, Ernest S. Smith